| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag |
|
Leukemia |
Aplastic Anemia |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
|
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Where There's Smoke, There's Fire: Inflammation Drives MDS |
|
Trends in immunology |
Myelodysplastic Syndromes (MDS) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
